Quick Answer
CorMedix Inc. reported Total Revenue of $311.71 million for fiscal year 2025.
CorMedix Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $311.71M +617.0% |
$43.47M | — | $65.4K -65.7% |
$190.9K -20.2% |
$239.2K -15.5% |
| Net Income | $163.06M +1009.4% |
-$17.93M +61.3% |
-$46.34M -56.0% |
-$29.70M -5.3% |
-$28.21M -28.1% |
-$22.03M -34.0% |
| Diluted EPS | $2.04 +780.0% |
-$0.30 +67.0% |
-$0.91 -23.0% |
-$0.74 +1.3% |
-$0.75 | — |
| Total Assets | $826.14M +595.1% |
$118.85M +44.8% |
$82.06M +32.3% |
$62.04M -10.0% |
$68.95M +39.8% |
$49.31M +67.3% |
| Cash and Equivalents | $144.84M +256.3% |
$40.65M -6.9% |
$43.64M +1.1% |
$43.15M -19.1% |
$53.32M +27.2% |
$41.91M +156.3% |
| Stockholders Equity | $405.31M +378.8% |
$84.66M +20.7% |
$70.14M +27.4% |
$55.06M -12.3% |
$62.80M +42.0% |
$44.22M +87.0% |
| R&D Expense | $19.33M +390.4% |
$3.94M -70.0% |
$13.16M +23.2% |
$10.68M -18.7% |
$13.13M -1.8% |
$13.38M +21.0% |
| Operating Income | $150.14M +771.6% |
-$22.36M +54.3% |
-$48.96M -59.9% |
-$30.62M -4.0% |
-$29.44M -8.1% |
-$27.22M -29.6% |
| Gross Profit | $275.75M +584.5% |
$40.28M | — | $61.7K +46.8% |
$42.0K +22.1% |
$34.4K +138.2% |
| Shares Outstanding | 79.26M +23.1% |
64.41M +17.2% |
54.94M +28.3% |
42.82M +12.4% |
38.09M +13.5% |
33.56M +30.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $104.28M | +810.2% | +162.4% |
| Net Income | September 30, 2025 | $108.56M | +4009.6% | +447.5% |
| Diluted EPS | September 30, 2025 | $1.26 | +2620.0% | +350.0% |
| Total Assets | September 30, 2025 | $750.86M | +867.8% | +197.3% |
| Cash and Equivalents | September 30, 2025 | $48.49M | +37.4% | -69.6% |
| Stockholders Equity | September 30, 2025 | $374.13M | +537.2% | +69.6% |
| R&D Expense | September 30, 2025 | $5.10M | +601.1% | +108.7% |
| Operating Income | September 30, 2025 | $51.35M | +1661.9% | +162.7% |
| Gross Profit | September 30, 2025 | $93.08M | +764.3% | +145.8% |
| Shares Outstanding | September 30, 2025 | 78.35M | +35.3% | +5.0% |
- CorMedix Inc. reported Total Revenue of $311.71 million for fiscal year 2025.
- CorMedix Inc. showed an increase of +617.0% in Total Revenue compared to the prior fiscal year.
- CorMedix Inc. reported Net Income of $163.06 million for fiscal year 2025.
- CorMedix Inc. showed an increase of +1009.4% in Net Income compared to the prior fiscal year.
- CorMedix Inc. reported Diluted EPS of $2.04 per share for fiscal year 2025.
- CorMedix Inc. showed an increase of +780.0% in Diluted EPS compared to the prior fiscal year.
- CorMedix Inc. reported Total Assets of $826.14 million for fiscal year 2025.
- CorMedix Inc. showed an increase of +595.1% in Total Assets compared to the prior fiscal year.
- CorMedix Inc. reported Cash and Equivalents of $144.84 million for fiscal year 2025.
- CorMedix Inc. showed an increase of +256.3% in Cash and Equivalents compared to the prior fiscal year.
- CorMedix Inc. reported Stockholders Equity of $405.31 million for fiscal year 2025.
- CorMedix Inc. showed an increase of +378.8% in Stockholders Equity compared to the prior fiscal year.
- CorMedix Inc. reported R&D Expense of $19.33 million for fiscal year 2025.
- CorMedix Inc. showed an increase of +390.4% in R&D Expense compared to the prior fiscal year.
- CorMedix Inc. reported Operating Income of $150.14 million for fiscal year 2025.
- CorMedix Inc. showed an increase of +771.6% in Operating Income compared to the prior fiscal year.
- CorMedix Inc. reported Gross Profit of $275.75 million for fiscal year 2025.
- CorMedix Inc. showed an increase of +584.5% in Gross Profit compared to the prior fiscal year.
- CorMedix Inc. reported Shares Outstanding of 79.26 million shares for fiscal year 2025.
- CorMedix Inc. showed an increase of +23.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: